Ziprasidone for maladaptive behavior and attention-deficit/hyperactivity disorder symptoms in autistic disorder [2]

Journal of Child and Adolescent Psychopharmacology

Volumn 17, Issue 2, 2007, Pages 261-263

  Duggal, Harpreet S ^a  

^a Herrick Memorial Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; METHYLPHENIDATE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADOLESCENT; AGGRESSION; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CASE REPORT; DRUG EFFICACY; DRUG SUBSTITUTION; HUMAN; INFANTILE AUTISM; LETTER; MALADJUSTMENT; MALE; SIDE EFFECT; SOCIAL ADAPTATION; SYMPTOMATOLOGY; WEIGHT GAIN;

ADOLESCENT; AGGRESSION; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUTISTIC DISORDER; CHILD BEHAVIOR DISORDERS; HUMANS; MALE; PIPERAZINES; THIAZOLES;

EID: 34249708283     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.00136     Document Type: Letter

References (11)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR): Washington, DC, American Psychiatric Association, 2000.
2. Arnold LE, Aman MG, Cook AM, Witwer AN, Hall KL, Thompson S, Ramadan Y: Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 45:1196-1205, 2006.
3. Cohen SA, Fitzgerald BJ, Khan SRF, Khan A: The effect of a switch to ziprasidone in an adult population with autistic disorder: Chart review of naturalistic, open-label treatment. J Clin Psychiatry 65:110-113, 2004.
4. Goforth HW, Rao MS: Improvement in behaviour and attention in an autistic patient treated with ziprasidone. Aust N Z J Psychiatry 37:775-776, 2003.
5. Harvey PD, Meltzer H, Simpson GM, Potkin SG, Loebel A, Siu C, Romano SJ: Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res. 66:101-113, 2004.
6. Leyfer OT, Folstein SE, Bacalman S, Davis NO, Dinh E, Morgan J, Tager-Flusberg H, Lainhart JE: Comorbid psychiatric disorders in children with autism: Interview development and rates of disorders. J Autism Dev Disord 36:849-861, 2006.
7. McDougle CJ, Kem DL, Posey DJ: Case series: Use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 41:921-927, 2002.
8. Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 19 (suppl 1):1-93, 2005.
9. Schmidt AW, Lebel LA, Howard Jr. HR, Zorn SH: Ziprasidone: A novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 425: 197-201, 2001.
10. Troost PW, Althaus M, Lahuis BE, Buitelaar JK, Minderaa RB, Hoekstra PJ: Neuropsychological effects of risperidone in children with pervasive developmental disorders: A blinded discontinuation study. J Child Adolesc Psychopharmacol 16:561-573, 2006.
11. Wilens TE: Mechanism of action of agents used in attention-deficit/ hyperactivity disorder. J Clin Psychiatry 67 (suppl 8):32-37, 2006.